Filtered By:
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 2143 results found since Jan 2013.
Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial
CONCLUSION: The pichia pastoris-expressed bivalent HPV vaccine was safe and immunogenic in Chinese females aged 9-45 years. The low dosage (0.5 mL) was selected for further immunogenicity and efficacy study.PMID:37061370 | DOI:10.1016/j.vaccine.2023.04.009
Source: Vaccine - April 15, 2023 Category: Allergy & Immunology Authors: Juan Li Li-Wei Shi Bang-Wei Yu Li-Rong Huang Ling-Yun Zhou Li Shi Zhi-Wei Jiang Jie-Lai Xia Xuan-Yi Wang Rong-Cheng Li Lin Yuan Yan-Ping Li Chang-Gui Li Source Type: research
Investigating the Efficacy of HPV Vaccines in Preventing Cervical Cancer from 2006 to 2018 in the US: A SEER Data Set Analysis
CONCLUSION: There seems to be little if any, correlation between cervical cancer incidence and the HPV vaccine program in the US. HPV vaccine efficacy based on alternative endpoints, such as nucleic acid testing and cytological, surgical, and seropositivity endpoints, is fair. Therefore, it is important to emphasize such alternative testing and surrogate endpoints.PMID:37046192 | DOI:10.2174/1574887118666230410093715
Source: Reviews on Recent Clinical Trials - April 12, 2023 Category: Cancer & Oncology Authors: Alexander Mattis Hind Beydoun Yuliya Dobrydneva Rohini Ganjoo Source Type: research
Estimating human papillomavirus vaccine efficacy from a single-arm trial: Proof-of-principle in the Costa Rica Vaccine Trial
CONCLUSION: We demonstrate that a single-arm design yields valid VE estimates with similar precision to an RCT. Single-arm studies can reduce the sample size and costs of future HPV vaccine trials while avoiding concerns related to unvaccinated control groups.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00128661.PMID:37040086 | DOI:10.1093/jnci/djad064
Source: Cancer Control - April 11, 2023 Category: Cancer & Oncology Authors: Brian Befano Nicole G Campos Didem Egemen Rolando Herrero Mark Schiffman Carolina Porras Douglas R Lowy Ana Cecilia Rodriguez John T Schiller Rebecca Ocampo Allan Hildesheim Joshua N Sampson Shrutikona Das Aim ée R Kreimer Li C Cheung Costa Rica HPV Vacc Source Type: research
Vaccine co-administration in adults: An effective way to improve vaccination coverage
Hum Vaccin Immunother. 2023 Apr 11:2195786. doi: 10.1080/21645515.2023.2195786. Online ahead of print.ABSTRACTThe ongoing COVID-19 pandemic highlights that complications and mortality associated with infectious diseases increase with age. Various vaccines are recommended for adults, but coverage rates remain suboptimal. Although co-administration would improve vaccine uptake and timely immunization, this is not routine practice in adults. We review key data on co-administration of vaccines in children and adults to reassure healthcare providers about its safety and advantages. In European countries and the United States, c...
Source: Herpes - April 11, 2023 Category: Infectious Diseases Authors: Paolo Bonanni Robert Steffen J örg Schelling Lina Balaisyte-Jazone Inga Posiuniene Maciej Zato ński Pierre Van Damme Source Type: research
Human papillomavirus vaccination receipt and provider counseling rates among high-risk patients
CONCLUSION: HPV vaccination and the rate of obstetric and gynecologic provider counseling regarding HPV vaccination among patients undergoing colposcopy remains low. When surveyed, many patients with a history of colposcopy cited provider recommendation as afactor in their decision to undergo adjuvant HPV vaccination, demonstrating the importance of provider counseling in thisgroup.PMID:37029002 | DOI:10.1016/j.vaccine.2023.03.073
Source: Vaccine - April 7, 2023 Category: Allergy & Immunology Authors: Stephanie M Wang Emma A Keegan Katherine M Bryan Jamil Kazma Kirsten J H Das Beverly J Long Anna BuAbbud Source Type: research
Patterns of HPV vaccine hesitancy among catch-up generations in Japan: A descriptive study
CONCLUSION: HPV vaccine awareness promotion strategies must be based on the characteristics of each group and the different distributions of sociodemographic factors.PMID:37024410 | DOI:10.1016/j.vaccine.2023.03.061
Source: Vaccine - April 6, 2023 Category: Allergy & Immunology Authors: Masaki Machida Shigeru Inoue Source Type: research
Advances in immunotherapy for cervical cancer
Ther Adv Med Oncol. 2023 Mar 28;15:17588359231163836. doi: 10.1177/17588359231163836. eCollection 2023.ABSTRACTCervical cancer still represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. These figures are unacceptable since cervical cancer, an human papillomavirus-related malignancy, is a largely preventable disease by means of well-established screening and vaccination programs. Patients with recurrent, persistent, or metastatic disease unsuitable for curative therapeutic approaches represent a dismal prognosis population. Until recently, these patient...
Source: Adv Data - April 3, 2023 Category: Epidemiology Authors: Juan Francisco Grau-Bejar Carmen Garcia-Duran David Garcia-Illescas Oriol Mirallas Ana Oaknin Source Type: research
Knowledge of Cervical Cancer and HPV, and Willingness to Receive HPV Vaccination Among 20-45-Year-Old Women - Six Provinces, China, 2018
China CDC Wkly. 2023 Mar 3;5(9):201-205. doi: 10.46234/ccdcw2023.036.ABSTRACTWHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: Cervical cancer is a significant public health problem with approximately 570,000 cases and 311,000 deaths occurring in 2018 globally. It is imperative to raise awareness of cervical cancer and human papillomavirus (HPV).WHAT IS ADDED BY THIS REPORT?: Compared to previous studies, this is one of the largest cross-sectional studies of cervical cancer and HPV in Chinese adult females in recent years. We found that knowledge level of cervical cancer and HPV vaccine was still inadequate among women aged 20-45 y...
Source: Cancer Control - April 3, 2023 Category: Cancer & Oncology Authors: Di Gao Gengli Zhao Jiangli Di Xiaosong Zhang Linhong Wang Source Type: research
